You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

Article metrics

Article menu

Download PDFPDF

Poster Presentation
Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma

 

Online download statistics by month:

Online download statistics by month: December 2019 to May 2026

AbstractFullPdf
Dec 2019010
Jan 2020031
Feb 2020031
May 2020010
Jun 2020050
Jul 2020010
Sep 2020040
Nov 2020020
Dec 2020010
Jan 2021040
Feb 2021010
Mar 2021010
Apr 2021070
May 2021010
Jul 2021010
Sep 2021031
Oct 2021021
Nov 2021054
Dec 2021020
Jan 2022090
Feb 2022010
Mar 2022041
Apr 2022010
May 2022051
Jun 2022040
Jul 2022021
Aug 2022071
Sep 2022052
Oct 2022010
Nov 2022060
Dec 2022060
Jan 2023021
Feb 2023030
Mar 2023010
Apr 2023030
May 2023010
Jun 2023011
Jul 2023011
Aug 2023032
Sep 2023040
Oct 2023021
Nov 2023042
Dec 2023030
Jan 2024010
Feb 2024060
Mar 2024052
Apr 2024060
May 2024030
Jun 2024041
Jul 2024032
Aug 2024042
Sep 2024063
Oct 2024042
Nov 2024042
Dec 2024041
Jan 2025032
Feb 2025012
Mar 2025041
Apr 20250121
May 20250412
Jun 20250117
Jul 2025010
Dec 2025010
Jan 2026030
May 2026010
Total021862